Evidence map›Paper›PMID 20618338›Full record

Trial reportBritish journal of haematology2010

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Paul G Richardson, Ashraf Z Badros, Sundar Jagannath, Stefano Tarantolo, Jeffrey L Wolf, Maher Albitar, David Berman, Marianne Messina, Kenneth C Anderson

Open access · greenAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Overview of Ferroptosis and Synthetic Lethality Strategies.International journal of molecular sciences · 2021
    Review
  12. Insights Into Bone Marrow Niche Stability: An Adhesion and Metabolism Route.Frontiers in cell and developmental biology · 2021
    Review
  13. Article
  14. Article
  15. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.International journal of molecular sciences · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Multiple Myeloma: Treatment is Getting Individualized.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Paul G RichardsonDana-Farber Cancer Institute, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu
Ashraf Z Badros
Sundar Jagannath
Stefano Tarantolo
Jeffrey L Wolf
Maher Albitar
David Berman
Marianne Messina
Kenneth C Anderson
Dana-Farber Cancer Institute · USBristol-Myers Squibb (Germany) · DEBristol-Myers Squibb (United States) · USHematology & Oncology Consultants · USQuest Diagnostics (United States) · USSaint Vincent Health System · USUniversity of California, San Francisco · USUniversity of Maryland Medical Center · US

Funding

Targeting Myeloma Cell-Host Bone Marrow InteractionsP01CA078378 · NCI · DANA-FARBER CANCER INSTITUTE · PI RITZ, JEROME · 1998 to 2014
$26.2M
NCI NIH HHS P01 CA078378
6 · The paper itself

Abstract

Tanespimycin (17-allylamino-17-demethoxygeldanamycin, 17-AAG) disrupts heat shock protein 90 (HSP90), a key molecular chaperone for signal transduction proteins critical to myeloma growth, survival and drug resistance. In previous studies, tanespimycin monotherapy was well tolerated and active in heavily pretreated patients with relapsed/refractory multiple myeloma (MM). Preclinical data have shown antitumour synergy between tanespimycin and bortezomib, with more pronounced intracellular accumulation of ubiquitinated proteins than either drug alone, an effect attributed to the synergistic suppression of chymotryptic activity in the 20S proteasome. HSP70 induction has been observed in all Phase 1 tanespimycin studies in which it has been measured, with several separate reports of HSP70 overexpression protecting against peripheral nerve injury. In this Phase 2, open-label multicentre study, we compared 1.3 mg/m2 bortezomib + three doses of tanespimycin: 50, 175 and 340 mg/m2 in heavily pretreated patients with relapsed and refractory MM and measured HSP70 expression and proteasome activity levels in plasma of treated patients. The study was closed prematurely for resource-based reasons, precluding dose comparison. Nonetheless, antitumour activity was observed, with promising response rates and promising severity of peripheral neuropathy.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzoquinonesBoronic AcidsBortezomibDose-Response Relationship, DrugDrug Administration ScheduleFemaleHSP70 Heat-Shock ProteinsHumansLactams, MacrocyclicLeukocyte CountMaleMiddle AgedMultiple MyelomaBenzoquinonesBoronic AcidsBortezomibHSP70 Heat-Shock ProteinsLactams, MacrocyclicPyrazinestanespimycin

Identifiers

PMID20618338
PMCPMC3418598
OpenAlexW1552240270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.